|
Carcinoma, Ovarian Epithelial
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Here, we demonstrated that PARP inhibitor (olaparib)-resistant epithelial ovarian cancer (EOC) cells exhibited an elevated aldehyde dehydrogenase (ALDH) activity, mainly contributed by increased expression of ALDH1A1 due to olaparib-induced expression of BRD4, a member of bromodomain and extraterminal (BET) family protein.
|
31534014 |
2020 |
|
Carcinoma, Ovarian Epithelial
|
0.090 |
Biomarker
|
disease |
BEFREE |
Inhibition of bromo and extra terminal (BET) proteins using BET bromodomain inhibitors blocked MEKi-induced RTK reprogramming, indicating that BRD2 and BRD4 represent promising therapeutic targets in combination with MEKi to block resistance due to kinome reprogramming in NF1-deficient EOC.
|
31043489 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.090 |
Biomarker
|
disease |
BEFREE |
Treatment with either BETis or BRD4 siRNA decreased Notch3 expression both <i>in vitro</i> and <i>in vivo</i> BRD4 inhibition also decreased the expression of <i>NOTCH3</i> targets, including <i>HES1</i> Chromatin immunoprecipitation revealed that BRD4 was present at the <i>NOTCH3</i> promoter.Our findings provide biological validation for the TPT by demonstrating that BETis can be an effective therapeutic agent for ovarian cancer by downregulating Notch3 expression.The TPT could rapidly identify candidate drugs for ovarian or other cancers along with novel companion biomarkers.
|
30420565 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.090 |
Biomarker
|
disease |
BEFREE |
Molecular design of Stat3-derived peptide selectivity between BET proteins Brd2 and Brd4 in ovarian cancer.
|
28983974 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Transcriptional profiling of BRD4-transformed ovarian cells, and BRD4-amplified HGSOC patient samples revealed shared expression patterns, including enriched MYC, and E2F1 gene signatures.
|
30036377 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.090 |
Biomarker
|
disease |
BEFREE |
Suppression of BRD4 using small-molecule BET inhibitors JQ1 and I-BET151, or dual kinase-bromodomain inhibitor volasertib, led to robust and broad antitumor effects across all subclasses of ovarian cancer.
|
26877780 |
2016 |
|
Carcinoma, Ovarian Epithelial
|
0.090 |
Biomarker
|
disease |
BEFREE |
An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma.
|
25535366 |
2015 |
|
Carcinoma, Ovarian Epithelial
|
0.090 |
Biomarker
|
disease |
BEFREE |
We report that BRD4, already identified as a target in several tumor models, is a new potential target in high grade non-BRCAness ovarian carcinoma.
|
25892415 |
2015 |
|
Carcinoma, Ovarian Epithelial
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Assessing the HER2 status in mucinous epithelial ovarian cancer on the basis of the 2013 ASCO/CAP guideline update.
|
25133707 |
2014 |